Press Releases - Emmaus Medical, Inc.

Endari® Granted Orphan Drug Status in SwitzerlandDecember 03, 2020

Emmaus Life Sciences, Inc., announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®.

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®November 10, 2020

Emmaus Life Sciences, Inc., announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain.

FDA Approves Updated Label for Endari®November 03, 2020

Emmaus Life Sciences, Inc., announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.

Emmaus Life Sciences Announces Informational Stockholders MeetingSeptember 01, 2020

Emmaus announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations.

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug AuthorityAugust 18, 2020

Emmaus announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia.